Catalog No.: PC-23369Not For Human Use, Lab Use Only.
BBI-2779 is a potent, selective and orally bioavailable inhibitor of CHK1 with biochemical IC50 of 0.5 nM and cellular IC50 of 3 nM (pCHK1-S345 activity in HT29 cells), 160-fold selective for CHK1 over CHK2.
BBI-2779 is a potent, selective and orally bioavailable inhibitor of CHK1 with biochemical IC50 of 0.5 nM and cellular IC50 of 3 nM (pCHK1-S345 activity in HT29 cells), 160-fold selective for CHK1 over CHK2.
BBI-2779 has superior biochemical and selective cell growth inhibition compared to other orally bioavailable CHK1 inhibitors.
BBI-2779 preferentially kills ecDNA-containing tumour cells, exhibits antiproliferation activity in COLO320DM cells with IC50 of 6 nM.
BBI-2779 suppresses tumour growth and prevents ecDNA-mediated acquired resistance to the pan-FGFR inhibitor infigratinib in gastric cancer model containing FGFR2 amplified on ecDNA, resulting in potent and sustained tumour regression in mice.
